Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 13Nausea 6Neoplasms 5Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Gynecologic Cancer 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 2Standard of Care 2Drug Therapy 2Brachytherapy 2gadobutrol 1fosaprepitant 1Therapeutics 1Surgical Procedures, Operative 1Sex 1Psychotherapy 1Prochlorperazine 1Preoperative Exercise 1Population Groups 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1Imagery, Psychotherapy 1FloSeal Matrix 1Ferric Oxide, Saccharated 1Exercise 1Enhanced Recovery After Surgery 1Educational Status 1Diagnostic Tests, Routine 1Diagnostic Imaging 1Dexamethasone 1Cryotherapy 1Counseling 1Cisplatin 1Blood Specimen Collection 1AGuIX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gynecologic Cancer × fosaprepitant × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡